240 related articles for article (PubMed ID: 17212981)
21. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
22. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
Mamasheva E; O'Donnell C; Bandekar A; Sofou S
Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
[TBL] [Abstract][Full Text] [Related]
25. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
Chiu SJ; Marcucci G; Lee RJ
Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of folate receptor-targeted and Doxorubicin-coupled chemotherapeutic nanoconjugate and research into its medical applications.
Ak G; Sanlıer SH
Prep Biochem Biotechnol; 2012; 42(6):551-63. PubMed ID: 23030466
[TBL] [Abstract][Full Text] [Related]
27. Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro.
Moradpour D; Compagnon B; Wilson BE; Nicolau C; Wands JR
Hepatology; 1995 Nov; 22(5):1527-37. PubMed ID: 7590672
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes.
Xiang G; Wu J; Lu Y; Liu Z; Lee RJ
Int J Pharm; 2008 May; 356(1-2):29-36. PubMed ID: 18258394
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.
Sawant RM; Cohen MB; Torchilin VP; Rokhlin OW
J Drug Target; 2008 Aug; 16(7):601-4. PubMed ID: 18686131
[TBL] [Abstract][Full Text] [Related]
30. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells.
Yip WL; Weyergang A; Berg K; Tønnesen HH; Selbo PK
Mol Pharm; 2007; 4(2):241-51. PubMed ID: 17263556
[TBL] [Abstract][Full Text] [Related]
31. Development of a bifunctional immunoliposome system for combined drug delivery and imaging in vivo.
Feng B; Tomizawa K; Michiue H; Han XJ; Miyatake S; Matsui H
Biomaterials; 2010 May; 31(14):4139-45. PubMed ID: 20149431
[TBL] [Abstract][Full Text] [Related]
32. Folate-PEG coated cationic modified chitosan--cholesterol liposomes for tumor-targeted drug delivery.
Wang H; Zhao P; Liang X; Gong X; Song T; Niu R; Chang J
Biomaterials; 2010 May; 31(14):4129-38. PubMed ID: 20163853
[TBL] [Abstract][Full Text] [Related]
33. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
[TBL] [Abstract][Full Text] [Related]
34. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
35. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells.
Wöll S; Dickgiesser S; Rasche N; Schiller S; Scherließ R
Eur J Pharm Biopharm; 2019 Mar; 136():203-212. PubMed ID: 30677497
[TBL] [Abstract][Full Text] [Related]
36. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.
del Carmen MG; Rizvi I; Chang Y; Moor AC; Oliva E; Sherwood M; Pogue B; Hasan T
J Natl Cancer Inst; 2005 Oct; 97(20):1516-24. PubMed ID: 16234565
[TBL] [Abstract][Full Text] [Related]
37. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
Malhi SS; Budhiraja A; Arora S; Chaudhari KR; Nepali K; Kumar R; Sohi H; Murthy RS
Int J Pharm; 2012 Aug; 432(1-2):63-74. PubMed ID: 22531856
[TBL] [Abstract][Full Text] [Related]
38. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer.
Vega J; Ke S; Fan Z; Wallace S; Charsangavej C; Li C
Pharm Res; 2003 May; 20(5):826-32. PubMed ID: 12751641
[TBL] [Abstract][Full Text] [Related]
39. Targeted magnetic liposomes loaded with doxorubicin.
Pradhan P; Banerjee R; Bahadur D; Koch C; Mykhaylyk O; Plank C
Methods Mol Biol; 2010; 605():279-93. PubMed ID: 20072888
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes.
Harding JA; Engbers CM; Newman MS; Goldstein NI; Zalipsky S
Biochim Biophys Acta; 1997 Jul; 1327(2):181-92. PubMed ID: 9271260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
